Abacavir and increased risk of myocardial infarction

The Lancet

Volumn 372, Issue 9641, 2008, Pages 805-

  Edwards, Ralph ^a   Bate, Andrew ^a   Lindquist, Marie ^a  

^a UPPSALA MONITORING CENTRE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; GLITAZONE DERIVATIVE;

DATA BASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEART INFARCTION; HUMAN; LETTER; MEDICAL RECORD; PRIORITY JOURNAL; RISK ASSESSMENT; WORLD HEALTH ORGANIZATION;

EID: 50649083281     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61333-1     Document Type: Letter

References (4)

1. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371 (2008) 1417-1426
2. Sanz E. Abacavir-myocardial infarction. WHO Signal (2005). http://www.who-umc.org/graphics/15962.pdf (accessed March 14, 2008).
3. Cutrell A., Brothers C., Yeo J., Hernandez J., and Lapierre D. Abacavir and the potential risk of myocardial infarction. Lancet 371 (2008) 1413
4. Bowdler J. Effective communications in pharmacovigilance. 1st edn. (1997), W Lake, Birmingham